Skip to main content
Clinical Trials/NCT03057171
NCT03057171
Unknown
Not Applicable

A Study on the Gastrointestinal Disease and Helicobacter Pylori Controlled Long Non-coding RNA

Yonsei University1 site in 1 country50 target enrollmentStarted: May 2015Last updated:

Overview

Phase
Not Applicable
Enrollment
50
Locations
1
Primary Endpoint
Expression of THRIL, PACER

Overview

Brief Summary

Helicobacter pylori (H.pylori) is a major human pathogenic bacterium in gastric mucosa which is linked to the development of gastritis, peptic ulcer disease, mucosa-associated lymphoid tissue lymphoma and gastric cancer. However the regulatory mechanism of H.pylori-induced immune response is not clear. Long non-coding RNA (lncRNA) has recently emerged as key post-transcriptional regulators of gene expression, differentiation. The investigators had a preliminary results which THRIL (TNFα and hnRNPL related immunoregulatory lincRNA) and PACER(p50-associated COX-2 extragenic RNA) played a potential role in H.pylori induced inflammatory cascade. However, there wasn't a previous study about expression of THRIL, PACER in a human tissue. Therefore, the investigators aimed to evaluate the expression of THRIL, PACER in patients with gastrointestinal disease according to H.pylori infection.

Study Design

Study Type
Observational
Observational Model
Case Only
Time Perspective
Prospective

Eligibility Criteria

Ages
19 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Over 19 years old
  • Patients with gastric ulcer
  • Patients with duodenal ulcer
  • Patients with stomach cancer
  • Patients with gastrointestinal discomfort symptoms

Exclusion Criteria

  • Patients who has done helicobacter pylori eradication
  • Patients who has undergone gastrectomy
  • Patients who has undergone endoscopic submucosal dissection
  • Patients with active upper gastrointestinal bleeding

Outcomes

Primary Outcomes

Expression of THRIL, PACER

Time Frame: Within 2 weeks after EGD

Expression of THRIL, PACER according to Helicobacter pylori infection by Real-time aRT-PCR

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials